Synopsis
0
JDMF
0
EU WC
0
KDMF
0
VMF
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers


1. Dl-amphetamine Sulfate
2. Amphetamine Sulphate
3. Phenaminum
4. 60-13-9
5. Amphamine Sulfate
6. Amphetamini Sulfas
7. Dl-phenamine Sulfate
8. Dl-amphetamine Sulphate
9. Amphetaminium Sulfuricum
10. Desoxynorephedrine Sulfate
11. (+-)-amphetamine Sulfate
12. Dl-amphetamine Hydrogen Sulfate
13. (+-)-phenisopropylamine Sulfate
14. Amfetamine Sulfate
15. Amphetamine Sulfate [usp]
16. Dl-1-phenyl-2-aminopropane Sulfate
17. (+-)-2-amino-1-phenylpropane Sulfate
18. (+-)-alpha-methylphenethylamine Sulfate (2:1)
19. 6dpv8nk46s
20. 1-phenylpropan-2-amine Sulfate (2:1)
21. Amphetamine Sulfate (usp)
22. Fenopromin Sulfate
23. Penamine (van)
24. Ccris 3644
25. 1-phenyl-2-aminopropane Sulfate
26. Cerm 1767
27. Razemisches Phenylaminopropansulfat
28. Dl-alpha-methylphenethylamine Sulfate
29. Einecs 200-457-8
30. Unii-6dpv8nk46s
31. Nsc 170999
32. Dl-amphetamine Sulfate Salt
33. Benzadrine
34. Alpha-methylphenethylamine Sulfate, (+-)-
35. Benzedrine (tn)
36. Evekeo (tn)
37. Evekeo Odt
38. Rac-amphetamine Sulphate
39. D-amphetamine Sulfate Salt
40. Schembl41204
41. Amphetamine Sulfate [mi]
42. Dtxsid4020082
43. Phenethylamine, Alpha-methyl-, Sulfate (2:1), (+-)-
44. Chebi:51063
45. Amfetamine Sulfate [mart.]
46. Amphetamine Sulfate [vandf]
47. Amfetamine Sulfate [who-dd]
48. Bis{1-phenylpropan-2-amine} Sulfate
49. Amfetamine Sulfate [ep Impurity]
50. Amfetamine Sulfate [ep Monograph]
51. Amphetamine Sulfate [orange Book]
52. .beta.-phenylisopyropylaminesulfate
53. Benzeneethanamine, Alpha-methyl-, Sulfate
54. Amphetamine Sulfate [usp Monograph]
55. Amfetamine Sulfate [incb:green List]
56. Delcobese Component Amphetamine Sulfate
57. D02074
58. (+/-)-2-amino-1-phenylpropane Sulfate
59. (+/-)-2-amino-1-phenylpropane Sulphate
60. Amphetamine Sulfate Component Of Delcobese
61. Q21270844
62. (+/-)-.alpha.-methylphenethylamine Sulfate (2:1)
63. (+/-)-.alpha.-methylphenethylamine Sulphate (2:1)
64. Benzeneethanamine, .alpha.-methyl-, Sulfate (2:1), (+/-)-
65. Benzeneethanamine, .alpha.-methyl-, Sulphate (2:1), (+/-)-
66. Dl-amphetamine Sulfate Salt Solution, Drug Standard, 1.0 Mg/ml In Methanol
67. 2-(tetrahydro-furan-2-yl)-n-(3-trifluoromethyl-phenyl)-succinamicacid
68. 156-31-0
1. Amfetamine
2. Mydrial
3. Desoxynorephedrine
4. L Amphetamine
| Molecular Weight | 368.5 g/mol |
|---|---|
| Molecular Formula | C18H28N2O4S |
| Hydrogen Bond Donor Count | 4 |
| Hydrogen Bond Acceptor Count | 6 |
| Rotatable Bond Count | 4 |
| Exact Mass | 368.17697855 g/mol |
| Monoisotopic Mass | 368.17697855 g/mol |
| Topological Polar Surface Area | 135 Ų |
| Heavy Atom Count | 25 |
| Formal Charge | 0 |
| Complexity | 166 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 2 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 3 |
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 14783
Submission : 2000-03-17
Status : Active
Type : II
NDC Package Code : 49812-0058
Start Marketing Date : 1999-01-01
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
| Available Reg Filing : CA |
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 15089
Submission : 2000-10-13
Status : Active
Type : II
NDC Package Code : 49812-0059
Start Marketing Date : 1999-01-01
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
| Available Reg Filing : CA |
GDUFA
DMF Review : Reviewed
Rev. Date : 2013-04-10
Pay. Date : 2013-04-03
DMF Number : 23583
Submission : 2010-03-04
Status : Active
Type : II
| Available Reg Filing : CA |
GDUFA
DMF Review : Reviewed
Rev. Date : 2013-04-10
Pay. Date : 2013-04-03
DMF Number : 24048
Submission : 2010-07-08
Status : Active
Type : II
| Available Reg Filing : CA |
GDUFA
DMF Review : Reviewed
Rev. Date : 2016-08-04
Pay. Date : 2015-08-27
DMF Number : 29601
Submission : 2016-02-25
Status : Active
Type : II
NDC Package Code : 0792-3939
Start Marketing Date : 2023-11-22
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT

GDUFA
DMF Review : Reviewed
Rev. Date : 2016-05-24
Pay. Date : 2015-08-27
DMF Number : 29604
Submission : 2016-02-25
Status : Active
Type : II
NDC Package Code : 0792-3936
Start Marketing Date : 2022-12-02
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT

GDUFA
DMF Review : Reviewed
Rev. Date : 2023-11-22
Pay. Date : 2023-11-03
DMF Number : 38836
Submission : 2023-10-20
Status : Active
Type : II

GDUFA
DMF Review : Reviewed
Rev. Date : 2013-03-17
Pay. Date : 2013-03-11
DMF Number : 15385
Submission : 2001-04-18
Status : Active
Type : II
Certificate Number : R0-CEP 2020-076 - Rev 00
Issue Date : 2021-07-26
Type : Chemical
Substance Number : 2752
Status : Valid
NDC Package Code : 0406-9450
Start Marketing Date : 2025-08-28
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT

GDUFA
DMF Review : Reviewed
Rev. Date : 2013-06-08
Pay. Date : 2013-05-31
DMF Number : 15425
Submission : 2001-05-09
Status : Active
Type : II
NDC Package Code : 0406-9451
Start Marketing Date : 2025-08-28
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT

GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 5378
Submission : 1984-02-09
Status : Inactive
Type : II

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
NDC Package Code : 49812-0058
Start Marketing Date : 1999-01-01
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 49812-0059
Start Marketing Date : 1999-01-01
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 59116-1942
Start Marketing Date : 2012-10-26
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT

NDC Package Code : 59116-1971
Start Marketing Date : 2012-10-26
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT

NDC Package Code : 61960-0200
Start Marketing Date : 2017-09-11
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT

NDC Package Code : 65392-0110
Start Marketing Date : 2018-04-24
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (10kg/10kg)
Marketing Category : BULK INGREDIENT FOR HUMAN P...

NDC Package Code : 65392-0114
Start Marketing Date : 2001-10-11
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (10kg/10kg)
Marketing Category : BULK INGREDIENT

NDC Package Code : 0406-1950
Start Marketing Date : 2013-04-29
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT

NDC Package Code : 0406-9450
Start Marketing Date : 2025-08-28
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT

NDC Package Code : 0406-9451
Start Marketing Date : 2025-08-28
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]About the Company : Veranova is a global leader in the development and manufacturing of specialist and complex APIs for pharma and biotech customers. We have over 50 years of experience navigating the...
About the Company : Driven by passion, our pharmaceutical products, expertise and technologies accelerate our customers’ small molecule therapeutics into markets across the world. With over 35 years...

About the Company : Driven by passion, our pharmaceutical products, expertise and technologies accelerate our customers’ small molecule therapeutics into markets across the world. With over 35 years...

About the Company : Chr. Olesen Synthesis is a Danish manufacturer of APIs and advanced intermediates. Chr. Olesen Synthesis was established in 2012 after the Chr. Olesen Group acquisition of the mult...

About the Company : We have been supporting the pharmaceutical and biopharmaceutical industries with drug development for over 30 years, assisting our clients in developing and bringing new drugs to m...

About the Company : We have been supporting the pharmaceutical and biopharmaceutical industries with drug development for over 30 years, assisting our clients in developing and bringing new drugs to m...

About the Company : We have been supporting the pharmaceutical and biopharmaceutical industries with drug development for over 30 years, assisting our clients in developing and bringing new drugs to m...

About the Company : At Embio, technology is the foundation of our success, driving leadership in every product we manufacture. With 30+ years of expertise in bacterial, fungal, and Category 1 GMO biot...

About the Company : Mallinckrodt Pharmaceuticals is a multibillion dollar specialty biopharmaceutical company focused on our mission: Managing Complexity. Improving Lives. We provide medicines to addr...

About the Company : Mallinckrodt Pharmaceuticals is a multibillion dollar specialty biopharmaceutical company focused on our mission: Managing Complexity. Improving Lives. We provide medicines to addr...

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us
Details:
Dextroamphetamine Sulfate is a non-catecholamine sympathomimetic amines with CNS stimulant activity. It is thought to block the reuptake of norepinephrine and dopamine into the presynaptic neuron and increase the release of these monoamines into the extraneuronal space.
Lead Product(s): Amphetamine Sulfate,Amphetamine Aspartate,Dextroamphetamine Saccharate
Therapeutic Area: Psychiatry/Psychology Brand Name: Amphetamine-Generic
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 24, 2023
Lead Product(s) : Amphetamine Sulfate,Amphetamine Aspartate,Dextroamphetamine Saccharate
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Granules Pharmaceuticals Inc., Receives ANDA Approval for Amphetamine Mixed Salts ER Capsules
Details : Dextroamphetamine Sulfate is a non-catecholamine sympathomimetic amines with CNS stimulant activity. It is thought to block the reuptake of norepinephrine and dopamine into the presynaptic neuron and increase the release of these monoamines into the extr...
Product Name : Amphetamine-Generic
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 24, 2023
Details:
FDA approved generic of Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate Tablets, for Attention Deficit Hyperactivity Disorder and Narcolepsy.
Lead Product(s): Dextroamphetamine Saccharate,Amphetamine Aspartate,Amphetamine Sulfate
Therapeutic Area: Psychiatry/Psychology Brand Name: Adderall-Generic
Study Phase: Approved FDFProduct Type: Controlled Substance
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 30, 2021
Lead Product(s) : Dextroamphetamine Saccharate,Amphetamine Aspartate,Amphetamine Sulfate
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Granules Pharmaceuticals Receives ANDA Approval for Amphetamine Mixed Salts (IR Tablets)
Details : FDA approved generic of Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate Tablets, for Attention Deficit Hyperactivity Disorder and Narcolepsy.
Product Name : Adderall-Generic
Product Type : Controlled Substance
Upfront Cash : Inapplicable
December 30, 2021
Details:
Amphetamine Sulfate is a Small Molecule drug candidate drug candidate, which is currently being evaluated in Phase IV clinical studies for the treatment of Attention Deficit Disorder with Hyperactivity.
Lead Product(s): Amphetamine Sulfate,Inapplicable
Therapeutic Area: Psychiatry/Psychology Brand Name: Undisclosed
Study Phase: Phase IVProduct Type: Miscellaneous
Sponsor: Premier Research Group
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 11, 2025

Lead Product(s) : Amphetamine Sulfate,Inapplicable
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase IV
Partner/Sponsor/Collaborator : Premier Research Group
Deal Size : Inapplicable
Deal Type : Inapplicable
ADZENYS XR-ODT™ in Children (4 to <6 Years) Diagnosed With Attention-deficit/Hyperactivity Disor...
Details : Amphetamine Sulfate is a Small Molecule drug candidate drug candidate, which is currently being evaluated in Phase IV clinical studies for the treatment of Attention Deficit Disorder with Hyperactivity.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 11, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Adderall-Generic is a CNS stimulant, which is indicated for the treatment of attention deficit hyperactivity disorder (ADHD) and Narcolepsy.
Lead Product(s): Dextroamphetamine Saccharate,Amphetamine Aspartate,Amphetamine Sulfate,Dextroamphetamine Sulphate
Therapeutic Area: Psychiatry/Psychology Brand Name: Adderall-Generic
Study Phase: Approved FDFProduct Type: Controlled Substance
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 17, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Dextroamphetamine Saccharate,Amphetamine Aspartate,Amphetamine Sulfate,Dextroamphetamine Sulphate
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Glenmark to Launch Generic Version of Adderall Tablets in the US Market by May 2025
Details : Adderall-Generic is a CNS stimulant, which is indicated for the treatment of attention deficit hyperactivity disorder (ADHD) and Narcolepsy.
Product Name : Adderall-Generic
Product Type : Controlled Substance
Upfront Cash : Inapplicable
April 17, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Adderall XR-Generic is a combination product of dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate & amphetamine sulfate. It is indicated for ADHD.
Lead Product(s): Dextroamphetamine Saccharate,Amphetamine Aspartate,Amphetamine Sulfate
Therapeutic Area: Psychiatry/Psychology Brand Name: Adderall XR-Generic
Study Phase: Approved FDFProduct Type: Controlled Substance
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 21, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Dextroamphetamine Saccharate,Amphetamine Aspartate,Amphetamine Sulfate
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lupin Receives FDA Approval for Generic Version of Adderall XR
Details : Adderall XR-Generic is a combination product of dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate & amphetamine sulfate. It is indicated for ADHD.
Product Name : Adderall XR-Generic
Product Type : Controlled Substance
Upfront Cash : Inapplicable
November 21, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
The agreement aims for the distribution and supply for Aytu's Adzenys XR-ODT and Cotempla XR-ODT product lines for the treatment of ADHD in Canada.
Lead Product(s): Amphetamine Sulfate,Inapplicable
Therapeutic Area: Psychiatry/Psychology Brand Name: Adzenys XR-ODT
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Lupin Pharma Canada
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement October 01, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Amphetamine Sulfate,Inapplicable
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Lupin Pharma Canada
Deal Size : Undisclosed
Deal Type : Agreement
Aytu BioPharma Partners with Lupin Canada For ADHD Drug Commercialization
Details : The agreement aims for the distribution and supply for Aytu's Adzenys XR-ODT and Cotempla XR-ODT product lines for the treatment of ADHD in Canada.
Product Name : Adzenys XR-ODT
Product Type : Miscellaneous
Upfront Cash : Undisclosed
October 01, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Tris Pharma and Perigon launched a direct-to-patient program, that allows patients and caregivers access to DYANAVEL XR (amphetamine) extended-release tablets through Perigon’s digital pharmacy and receive assistance and support to help navigate their treatment journey.
Lead Product(s): Amphetamine Sulfate,Inapplicable
Therapeutic Area: Psychiatry/Psychology Brand Name: Dyanavel XR
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Perigon Pharmacy 360
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership October 30, 2023

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Amphetamine Sulfate,Inapplicable
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Perigon Pharmacy 360
Deal Size : Undisclosed
Deal Type : Partnership
Tris Pharma Partners with Perigon Pharmacy 360 to Enhance Access to DYANAVEL® XR Tablets for the ...
Details : Tris Pharma and Perigon launched a direct-to-patient program, that allows patients and caregivers access to DYANAVEL XR (amphetamine) extended-release tablets through Perigon’s digital pharmacy and receive assistance and support to help navigate their ...
Product Name : Dyanavel XR
Product Type : Miscellaneous
Upfront Cash : Undisclosed
October 30, 2023

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Under the agreement, Aardvark will acquire certain assets and intellectual property of the Company that pertain to ADAIR, a proprietary abuse-deterrent formulation of immediate release dextroamphetamine, for the development of certain follow-on pipeline programs.
Lead Product(s): Amphetamine Sulfate,Inapplicable
Therapeutic Area: Psychiatry/Psychology Brand Name: ADAIR
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Aardvark Therapeutics
Deal Size: $80.0 million Upfront Cash: Undisclosed
Deal Type: Agreement August 23, 2023

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Amphetamine Sulfate,Inapplicable
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Aardvark Therapeutics
Deal Size : $80.0 million
Deal Type : Agreement
Details : Under the agreement, Aardvark will acquire certain assets and intellectual property of the Company that pertain to ADAIR, a proprietary abuse-deterrent formulation of immediate release dextroamphetamine, for the development of certain follow-on pipeline ...
Product Name : ADAIR
Product Type : Miscellaneous
Upfront Cash : Undisclosed
August 23, 2023

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Under the agreement, Medomie will commercialize Adzenys XR-ODT (amphetamine) and Cotempla XR-ODT (methylphenidate) in Israel and the Palestinian Authority.
Lead Product(s): Amphetamine Sulfate,Inapplicable
Therapeutic Area: Psychiatry/Psychology Brand Name: Adzenys XR
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Aytu BioPharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement July 31, 2023

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Amphetamine Sulfate,Inapplicable
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Aytu BioPharma
Deal Size : Undisclosed
Deal Type : Agreement
Details : Under the agreement, Medomie will commercialize Adzenys XR-ODT (amphetamine) and Cotempla XR-ODT (methylphenidate) in Israel and the Palestinian Authority.
Product Name : Adzenys XR
Product Type : Miscellaneous
Upfront Cash : Undisclosed
July 31, 2023

Details:
Amphetamine is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Attention Deficit Disorder with Hyperactivity.
Lead Product(s): Amphetamine Sulfate,Methylphenidate
Therapeutic Area: Psychiatry/Psychology Brand Name: Undisclosed
Study Phase: Phase IVProduct Type: Miscellaneous
Sponsor: Patient-Centered Outcomes Research Institute | University of California, Irvine | Holland Bloorview Kids Rehabilitation Hospital | Children's Hospital of Philadelphia | University of Rochester | Nationwide Children’s Hospital | Children's Hospital Medical
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 23, 2023

Lead Product(s) : Amphetamine Sulfate,Methylphenidate
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase IV
Partner/Sponsor/Collaborator : Patient-Centered Outcomes Research Institute | University of California, Irvine | Holland Bloorview Kids Rehabilitation Hospital | Children's Hospital of Philadelphia | University of Rochester | Nationwide Children’s Hospital | Children's Hospital Medical
Deal Size : Inapplicable
Deal Type : Inapplicable
AWARE: Management of ADHD in Autism Spectrum Disorder
Details : Amphetamine is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Attention Deficit Disorder with Hyperactivity.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 23, 2023

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]dl-1-Chloro-1-phenyl-2-aminopropane Hydrochloride
CAS Number : 25394-33-6
End Use API : Amphetamine Sulfate
About The Company : Malladi Drugs & Pharmaceuticals Ltd was founded in 1980 by microbiologist Mr. M L N Sastry. Within a few years, Malladi established itself as a leader in manufa...
CAS Number : 3182-95-4
End Use API : Amphetamine Sulfate
About The Company : PMC Isochem is a CDMO company acquired by PMC International in 2017. It manufactures cGMP intermediates, active pharmaceutical ingredients and functional excipi...
Phenyl Acetone OR 1-Phenyl-2-Peopanone
CAS Number : 103-79-7
End Use API : Amphetamine Sulfate
About The Company : Maisuriya Pharma Solutions is a research-driven & technology-oriented company. Continuous innovations & improvement are the lifeblood of our business. Our major...

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Regulatory Info :
Registration Country : India
Brand Name : Amphetamine
Dosage Form : Tablet
Dosage Strength : 5MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : India
Packaging :
Regulatory Info :
Dosage : Tablet
Dosage Strength : 5MG
Brand Name : Amphetamine
Approval Date :
Application Number :
Registration Country : India
Regulatory Info :
Registration Country : India
Brand Name : Amphetamine
Dosage Form : Tablet
Dosage Strength : 10MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : India
Packaging :
Regulatory Info :
Dosage : Tablet
Dosage Strength : 10MG
Brand Name : Amphetamine
Approval Date :
Application Number :
Registration Country : India
Regulatory Info :
Registration Country : India
Brand Name : Amphetamine
Dosage Form : Tablet
Dosage Strength : 15MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : India
Packaging :
Regulatory Info :
Dosage : Tablet
Dosage Strength : 15MG
Brand Name : Amphetamine
Approval Date :
Application Number :
Registration Country : India
Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.
Regulatory Info :
Registration Country : India
Brand Name : Mixed Amphetamines
Dosage Form : Extended Release Capsu...
Dosage Strength : 5MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : India
Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.
Packaging :
Regulatory Info :
Dosage : Extended Release Capsu...
Dosage Strength : 5MG
Brand Name : Mixed Amphetamines
Approval Date :
Application Number :
Registration Country : India
Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.
Regulatory Info :
Registration Country : India
Brand Name : Mixed Amphetamines
Dosage Form : Extended Release Capsu...
Dosage Strength : 10MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : India
Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.
Packaging :
Regulatory Info :
Dosage : Extended Release Capsu...
Dosage Strength : 10MG
Brand Name : Mixed Amphetamines
Approval Date :
Application Number :
Registration Country : India
Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.
Regulatory Info :
Registration Country : India
Brand Name : Mixed Amphetamines
Dosage Form : Extended Release Capsu...
Dosage Strength : 25MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : India
Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.
Packaging :
Regulatory Info :
Dosage : Extended Release Capsu...
Dosage Strength : 25MG
Brand Name : Mixed Amphetamines
Approval Date :
Application Number :
Registration Country : India
Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.
Regulatory Info :
Registration Country : India
Brand Name : Mixed Amphetamines
Dosage Form : Extended Release Capsu...
Dosage Strength : 30MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : India
Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.
Packaging :
Regulatory Info :
Dosage : Extended Release Capsu...
Dosage Strength : 30MG
Brand Name : Mixed Amphetamines
Approval Date :
Application Number :
Registration Country : India
Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.
Regulatory Info :
Registration Country : India
Brand Name : Mixed Amphetamines
Dosage Form : Immediate Release Tabl...
Dosage Strength : 5MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : India
Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.
Packaging :
Regulatory Info :
Dosage : Immediate Release Tabl...
Dosage Strength : 5MG
Brand Name : Mixed Amphetamines
Approval Date :
Application Number :
Registration Country : India
Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.
Regulatory Info :
Registration Country : India
Brand Name : Mixed Amphetamines
Dosage Form : Immediate Release Tabl...
Dosage Strength : 10MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : India
Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.
Packaging :
Regulatory Info :
Dosage : Immediate Release Tabl...
Dosage Strength : 10MG
Brand Name : Mixed Amphetamines
Approval Date :
Application Number :
Registration Country : India
Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.
Regulatory Info :
Registration Country : India
Brand Name : Mixed Amphetamines
Dosage Form : Immediate Release Tabl...
Dosage Strength : 20MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : India
Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.
Packaging :
Regulatory Info :
Dosage : Immediate Release Tabl...
Dosage Strength : 20MG
Brand Name : Mixed Amphetamines
Approval Date :
Application Number :
Registration Country : India
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Excipients by Applications
Global Sales Information
Company : Teva USA
Dextroamphetamine/Amphetamine
Drug Cost (USD) : 9,672,998
Year : 2023
Prescribers : 4019
Prescriptions : 15123

Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company : Takeda Pharmace
Dextroamphetamine/Amphetamine
Drug Cost (USD) : 17,043,346
Year : 2023
Prescribers : 14292
Prescriptions : 53604

Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company : Neos Brands/Ayt
Amphetamine
Drug Cost (USD) : 1,168,346
Year : 2023
Prescribers : 466
Prescriptions : 1972

Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company : Amneal Pharmace
Amphetamine Sulfate
Drug Cost (USD) : 85,954
Year : 2023
Prescribers : 102
Prescriptions : 391

Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company : Dr.Reddy'S Lab
Amphetamine Sulfate
Drug Cost (USD) : 22,854
Year : 2023
Prescribers : 42
Prescriptions : 106

Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company : Granules Pharma
Amphetamine Sulfate
Drug Cost (USD) : 48,835
Year : 2023
Prescribers : 81
Prescriptions : 227

Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company : Lannett Co. Inc
Amphetamine Sulfate
Drug Cost (USD) : 24,741
Year : 2023
Prescribers : 32
Prescriptions : 108

Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company : Amneal Pharmace
Dextroamphetamine Sulfate
Drug Cost (USD) : 2,315,274
Year : 2023
Prescribers : 160
Prescriptions : 1045

Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company : Aurobindo Pharm
Dextroamphetamine Sulfate
Drug Cost (USD) : 56,605
Year : 2023
Prescribers : 682
Prescriptions : 958

Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company : KVK-Tech, Inc.
Dextroamphetamine Sulfate
Drug Cost (USD) : 374,982
Year : 2023
Prescribers : 2342
Prescriptions : 4395

Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Dosage Form : CAPSULE, EXTENDED RELEASE;ORAL
Dosage Strength : 5MG
Price Per Pack :
Published in :
Country : USA
RX/OTC/DISCN : RX

Dosage Form : CAPSULE, EXTENDED RELEASE;ORAL
Dosage Strength : 10MG
Price Per Pack :
Published in :
Country : USA
RX/OTC/DISCN : RX

Dosage Form : CAPSULE, EXTENDED RELEASE;ORAL
Dosage Strength : 15MG
Price Per Pack :
Published in :
Country : USA
RX/OTC/DISCN : RX

Dosage Form : CAPSULE, EXTENDED RELEASE;ORAL
Dosage Strength : 5MG
Price Per Pack :
Published in :
Country : USA
RX/OTC/DISCN : RX

Dosage Form : CAPSULE, EXTENDED RELEASE;ORAL
Dosage Strength : 10MG
Price Per Pack :
Published in :
Country : USA
RX/OTC/DISCN : RX

Dosage Form : CAPSULE, EXTENDED RELEASE;ORAL
Dosage Strength : 15MG
Price Per Pack :
Published in :
Country : USA
RX/OTC/DISCN : RX

Dosage Form : CAPSULE, EXTENDED RELEASE;ORAL
Dosage Strength : 5MG
Price Per Pack :
Published in :
Country : USA
RX/OTC/DISCN : DISCN

Medice Arzneimittel Pütter GmbH & ...
Dosage Form : Antic-calc Tablet
Dosage Strength : 10 mg
Price Per Pack (Euro) : 62.062
Published in :
Country : Norway
RX/OTC/DISCN :

Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Medice Arzneimittel Pütter GmbH & ...
Dosage Form : Antic-calc Tablet
Dosage Strength : 20 mg
Price Per Pack (Euro) : 92.851
Published in :
Country : Norway
RX/OTC/DISCN :

Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Medice Arzneimittel Pütter GmbH & ...
Dosage Form : Antic-calc Tablet
Dosage Strength : 5 mg
Price Per Pack (Euro) : 35.431
Published in :
Country : Norway
RX/OTC/DISCN :

Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Amphetamine, Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate, Amphetamine Sulfate
Amphetamine, Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate, Amphetamine Sulfate
Main Therapeutic Indication : CNS & Anesthesia
Currency : USD
2019 Revenue in Millions : 190
2018 Revenue in Millions : 0
Growth (%) : N/A

Amphetamine, Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate, Amphetamine Sulfate
Amphetamine, Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate, Amphetamine Sulfate
Main Therapeutic Indication : CNS & Anesthesia
Currency : USD
2020 Revenue in Millions : 215
2019 Revenue in Millions : 194
Growth (%) : 11

Amphetamine, Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate, Amphetamine Sulfate
Amphetamine, Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate, Amphetamine Sulfate
Main Therapeutic Indication : Neurology
Currency : USD
2021 Revenue in Millions : 171
2020 Revenue in Millions : 207
Growth (%) : -11

Amphetamine, Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate, Amphetamine Sulfate
Amphetamine, Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate, Amphetamine Sulfate
Main Therapeutic Indication : Neurology
Currency : USD
2022 Revenue in Millions : 184
2021 Revenue in Millions : 171
Growth (%) : 8

Amphetamine, Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate, Amphetamine Sulfate
Amphetamine, Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate, Amphetamine Sulfate
Main Therapeutic Indication : Neurology
Currency : USD
2023 Revenue in Millions : 305
2022 Revenue in Millions : 184
Growth (%) : 87

Amphetamine, Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate, Amphetamine Sulfate
Amphetamine, Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate, Amphetamine Sulfate
Main Therapeutic Indication : Neurology
Currency : USD
2024 Revenue in Millions : 207
2023 Revenue in Millions : 304
Growth (%) : -32

Amphetamine, Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate, Amphetamine Sulfate
Amphetamine, Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate, Amphetamine Sulfate
Main Therapeutic Indication : Neurological/Mental Disorders
Currency : USD
2016 Revenue in Millions : 364
2015 Revenue in Millions : 363
Growth (%) : 0

Amphetamine, Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate, Amphetamine Sulfate
Amphetamine, Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate, Amphetamine Sulfate
Main Therapeutic Indication : Neurological/Mental Disorders
Currency : USD
2017 Revenue in Millions : 348
2016 Revenue in Millions : 364
Growth (%) : -4

Mixed Salts of a Single-Entity Amphetamine
Main Therapeutic Indication : Neurological/Mental Disorders
Currency : USD
2017 Revenue in Millions : 22
2016 Revenue in Millions : 0
Growth (%) : New Launch

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Market Place
Reply
30 Apr 2025
Reply
19 Jul 2024
Reply
18 Apr 2024
Reply
30 May 2023
Reply
23 Sep 2022
Reply
30 Sep 2021
Reply
20 Aug 2021
Reply
17 Dec 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Reply
20 Jun 2024

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
Noramco is a partner to the pharmaceutical industry for controlled substance development & manufacturing.
CAS Number : 22148-75-0
Quantity Per Vial :
Sale Unit :
Price :
Details : N-formylamphetamine
Monograph : 51634-2040
Storage :
Code/Batch No :
Noramco is a partner to the pharmaceutical industry for controlled substance development & manufacturing.
CAS Number : 60-13-9
Quantity Per Vial :
Sale Unit :
Price :
Details : USP Impurity
Monograph : 51634-2024
Storage :
Code/Batch No :
Noramco is a partner to the pharmaceutical industry for controlled substance development & manufacturing.
Dextroamphetamine Sulfate (CII)
CAS Number : 51-63-8
Quantity Per Vial :
Sale Unit :
Price :
Details : USP Impurity
Monograph : 51634-2022
Storage :
Code/Batch No :
Noramco is a partner to the pharmaceutical industry for controlled substance development & manufacturing.
Dextroamphetamine Sulfate, < 98% EE (CII)
CAS Number : 51-63-8
Quantity Per Vial :
Sale Unit :
Price :
Details :
Monograph : 51634-2022
Storage :
Code/Batch No :
CAS Number :
Quantity Per Vial :
Sale Unit :
Price :
Details :
Monograph :
Storage :
Code/Batch No : 730

Dextroamphetamine Related Compound A (25 mg) ...
CAS Number : 698-87-3
Quantity Per Vial : 25
Sale Unit : mg
Price : $775.00
Details : Material Origin- Chemical Synthesis; USMCA- N...
Monograph :
Storage :
Code/Batch No : Catalog #1180015 / F0H131

Dextroamphetamine Related Compound B CII (25 ...
CAS Number : 103-79-7
Quantity Per Vial : 25
Sale Unit : mg
Price : $775.00
Details : Material Origin- Chemical Synthesis; USMCA- N...
Monograph :
Storage :
Code/Batch No : Catalog #1180026 / R097P0

Dextroamphetamine Sulfate CII (500 mg)
CAS Number : 51-63-8
Quantity Per Vial : 500
Sale Unit : mg
Price : $340.00
Details : Material Origin- Chemical Synthesis; USMCA- Y...
Monograph :
Storage :
Code/Batch No : Catalog #1180004 / R102M0

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]ABOUT THIS PAGE
54
PharmaCompass offers a list of Amphetamine Sulfate API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Amphetamine Sulfate manufacturer or Amphetamine Sulfate supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Amphetamine Sulfate manufacturer or Amphetamine Sulfate supplier.
PharmaCompass also assists you with knowing the Amphetamine Sulfate API Price utilized in the formulation of products. Amphetamine Sulfate API Price is not always fixed or binding as the Amphetamine Sulfate Price is obtained through a variety of data sources. The Amphetamine Sulfate Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Amphetamine manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Amphetamine, including repackagers and relabelers. The FDA regulates Amphetamine manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Amphetamine API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Amphetamine manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Amphetamine supplier is an individual or a company that provides Amphetamine active pharmaceutical ingredient (API) or Amphetamine finished formulations upon request. The Amphetamine suppliers may include Amphetamine API manufacturers, exporters, distributors and traders.
click here to find a list of Amphetamine suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Amphetamine DMF (Drug Master File) is a document detailing the whole manufacturing process of Amphetamine active pharmaceutical ingredient (API) in detail. Different forms of Amphetamine DMFs exist exist since differing nations have different regulations, such as Amphetamine USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Amphetamine DMF submitted to regulatory agencies in the US is known as a USDMF. Amphetamine USDMF includes data on Amphetamine's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Amphetamine USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Amphetamine suppliers with USDMF on PharmaCompass.
A Amphetamine CEP of the European Pharmacopoeia monograph is often referred to as a Amphetamine Certificate of Suitability (COS). The purpose of a Amphetamine CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Amphetamine EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Amphetamine to their clients by showing that a Amphetamine CEP has been issued for it. The manufacturer submits a Amphetamine CEP (COS) as part of the market authorization procedure, and it takes on the role of a Amphetamine CEP holder for the record. Additionally, the data presented in the Amphetamine CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Amphetamine DMF.
A Amphetamine CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Amphetamine CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Amphetamine suppliers with CEP (COS) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Amphetamine as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Amphetamine API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Amphetamine as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Amphetamine and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Amphetamine NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Amphetamine suppliers with NDC on PharmaCompass.
Amphetamine Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Amphetamine GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Amphetamine GMP manufacturer or Amphetamine GMP API supplier for your needs.
A Amphetamine CoA (Certificate of Analysis) is a formal document that attests to Amphetamine's compliance with Amphetamine specifications and serves as a tool for batch-level quality control.
Amphetamine CoA mostly includes findings from lab analyses of a specific batch. For each Amphetamine CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Amphetamine may be tested according to a variety of international standards, such as European Pharmacopoeia (Amphetamine EP), Amphetamine JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Amphetamine USP).